The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 20, 2018

Filed:

May. 12, 2014
Applicant:

Cancer Vaccine Institute, London, GB;

Inventors:

Angus Dalgleish, London, GB;

Rachel Allen, London, GB;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/485 (2006.01); A61K 39/39 (2006.01); A61K 45/06 (2006.01); A61K 31/593 (2006.01); A61K 39/04 (2006.01); C07D 489/08 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39 (2013.01); A61K 31/485 (2013.01); A61K 31/593 (2013.01); A61K 39/04 (2013.01); A61K 45/06 (2013.01); C07D 489/08 (2013.01); A61K 2039/55511 (2013.01); A61K 2039/585 (2013.01);
Abstract

The present invention provides novel therapeutic applications of low dose naltrexone (LDN). Said applications have been determined in light of the discovery by the present inventors that naltrexone acts as an antagonist of Toll-like receptor 9 (TLR9), an innate immune receptor which elicits the production of inflammatory cytokines when agonized. Chronic inflammation and TLR9 overexpression are characteristics of a number of disorders, including certain cancers. Accordingly, the present invention provides novel uses of naltrexone in the treatment of a subject having a disorder characterized by TLR9 overexpression and/or overactivity of TLR9-mediated signalling. The present invention also provides novel uses of naltrexone in the supportive care of subject having a tumor/cancer, and methods of treating and providing supportive care to a subject, comprising the administration of naltrexone.


Find Patent Forward Citations

Loading…